Last updated: September 8, 2026
MYALEPT, the commercial brand for metreleptin, is a rare-disease biologic approved in the United States for lipodystrophy-associated leptin deficiency. Its market is small, specialist-driven, and heavily dependent on reimbursement and patient identification. The product generated approximately $180 million in annual revenue for Amryt before Chiesi acquired the company in 2023. MYALEPT remains commercially protected by regulatory complexity, orphan-disease concentration, limited clinical alternatives, and manufacturing requirements rather than by a broad mass-market franchise.
The principal long-term risks are orphan exclusivity expiry, payer pressure, potential biosimilar development, safety monitoring, and the absence of a large eligible patient population.
What is MYALEPT and what disease does it treat?
MYALEPT is recombinant human leptin, marketed as metreleptin. It is administered by subcutaneous injection and is used as replacement therapy in patients with congenital or acquired generalized lipodystrophy. The FDA approval does not extend broadly to all forms of lipodystrophy or to ordinary obesity and metabolic disease.
The product addresses a rare endocrine disorder in which inadequate adipose tissue and leptin deficiency contribute to severe insulin resistance, hypertriglyceridemia, diabetes, and hepatic steatosis. Treatment is generally managed by metabolic disease specialists and requires patient selection, dosing based on body weight, and monitoring for antibody formation and other safety issues.
| Product |
Active ingredient |
FDA approval |
Approved use |
Sponsor history |
| MYALEPT |
Metreleptin |
February 24, 2014 |
Congenital or acquired generalized lipodystrophy |
Aegerion, Amryt, now Chiesi |
| Form |
Recombinant protein |
Biologic license application |
Subcutaneous injection |
BLA 125546 |
| Primary market |
United States |
Orphan-disease market |
Leptin-deficiency replacement |
Specialist and specialty-pharmacy channels |
The FDA granted MYALEPT orphan-drug designation. The product carries a boxed warning for the risk of anti-metreleptin antibodies with neutralizing activity and lymphoma. The label also warns about serious hypersensitivity reactions and hypoglycemia in patients receiving insulin or insulin secretagogues.[1]
How large is the MYALEPT market?
The MYALEPT market is a high-value, low-volume specialty market. Revenue is driven more by annual treatment value per patient than by prescription volume.
The addressable population is limited because MYALEPT is approved for generalized lipodystrophy, which is substantially less prevalent than partial lipodystrophy or common metabolic disease. The company has not disclosed a large, independently verified global treated-patient base comparable with mainstream rare-disease products.
The market has several structural characteristics:
- Diagnosis is difficult and often delayed.
- Patients frequently require complex metabolic care.
- Treatment is chronic rather than episodic.
- Reimbursement depends on documentation of the underlying lipodystrophy diagnosis.
- There are few direct pharmacologic substitutes for leptin replacement.
The United States is the core commercial market. Regulatory approvals or availability outside the United States have not produced a comparable revenue base. Market expansion therefore depends on diagnosis, referral networks, payer access, and treatment persistence rather than broad geographic penetration.
What has MYALEPT’s financial trajectory been?
MYALEPT was one of Amryt’s principal revenue-generating products before Chiesi acquired Amryt. Public company disclosures indicate that MYALEPT annual revenue reached the high-$100 million range.
| Fiscal year |
Reported MYALEPT revenue |
Commercial context |
| 2020 |
Approximately $160 million |
Continued specialty-market expansion |
| 2021 |
Approximately $160 million to $165 million |
Stable demand and patient-base growth |
| 2022 |
Approximately $180 million to $185 million |
Strong contribution to Amryt revenue |
| 2023 onward |
Not separately disclosed by Chiesi |
Product incorporated into Chiesi’s rare-disease portfolio |
Amryt reported total revenue of roughly $280 million in 2022, with MYALEPT contributing approximately two-thirds of the company’s sales. The product’s contribution gave Amryt a concentrated but valuable revenue stream before the acquisition by Chiesi.[2]
Chiesi completed its acquisition of Amryt in April 2023 in a transaction valued at approximately $1.25 billion. MYALEPT became part of Chiesi’s rare-disease business alongside products such as Mycapssa and Myalept-related metabolic therapies.[3]
Chiesi does not provide the same level of product-level revenue detail that Amryt provided as a public company. That limits direct assessment of post-acquisition MYALEPT growth, pricing, and profitability. The product remains commercially important, but its current revenue is embedded within Chiesi’s broader specialty and rare-disease reporting.
What drives MYALEPT revenue?
MYALEPT revenue depends on five principal factors:
- Growth in diagnosed generalized lipodystrophy cases.
- Persistence among patients who respond clinically.
- Annual net price after rebates and discounts.
- Coverage by commercial insurers and government programs.
- Continued absence of an approved biosimilar or direct replacement.
Because the treated population is small, a modest change in patient count can materially affect annual sales. Conversely, price increases can support revenue growth without a corresponding increase in volume, although payer resistance and utilization controls limit that strategy.
When did MYALEPT lose orphan exclusivity?
MYALEPT received seven years of U.S. orphan-drug exclusivity beginning with its February 2014 approval. That period generally expired in February 2021.[1]
Orphan exclusivity prevents FDA approval of another drug for the same orphan indication during the exclusivity period, subject to statutory exceptions. Its expiry removed the regulatory barrier that had protected MYALEPT from approval of another product for the same indication. It did not automatically create a commercially viable competitor.
The end of orphan exclusivity did not eliminate:
- Patent rights, if enforceable and unexpired.
- Trade-secret protection for manufacturing processes.
- Regulatory complexity associated with a biologic.
- Clinical and reimbursement barriers to entering the generalized-lipodystrophy market.
- The need to establish biosimilarity or clinical comparability.
What is the FDA regulatory status of MYALEPT?
MYALEPT is approved under BLA 125546. It is a biologic product, not a conventional small-molecule drug. A competing manufacturer would generally pursue a biosimilar pathway under section 351(k) of the Public Health Service Act rather than an abbreviated new drug application under section 505(j).
The principal regulatory issues include:
| Regulatory issue |
Impact on competition |
| Biologic status |
Requires a biosimilar development program |
| Rare disease |
Limits trial recruitment and commercial return |
| Neutralizing antibodies |
Requires immunogenicity assessment |
| Weight-based dosing |
Complicates comparative exposure analysis |
| Orphan indication |
Limits addressable market |
| Specialty distribution |
Requires payer and provider infrastructure |
MYALEPT is not a conventional Orange Book generic opportunity. Biologics licensed through a BLA are generally managed through the Purple Book framework, which identifies biological products and biosimilar relationships. The relevant competitive question is therefore whether a manufacturer develops a biosimilar or another biologic leptin-replacement product, not whether an ANDA filer launches a tablet or conventional injectable generic.[4]
What patents protect MYALEPT?
MYALEPT protection has included patents and patent-family rights relating to metreleptin, treatment of lipodystrophy, formulations, dosing, and manufacturing. The commercial value of these rights must be analyzed separately from FDA exclusivity because orphan exclusivity expired in 2021.
Publicly available product information does not establish a single, universally accepted terminal patent date that independently determines market entry. For a biologic such as metreleptin, the practical protection profile depends on:
- The specific patent claims.
- Patent-term adjustment and any pediatric extension.
- Whether claims cover the active molecule, formulation, dosing regimen, or method of treatment.
- Patent-family prosecution and continuation practice.
- Biosimilar interchangeability and litigation timing.
- Manufacturing know-how and cell-culture controls.
Are formulation patents important for MYALEPT?
Formulation patents can be important because metreleptin is a protein product with stability, aggregation, storage, and immunogenicity considerations. A competitor may be able to design around a formulation claim while still facing development costs associated with demonstrating comparable quality and clinical performance.
The commercial barrier is therefore broader than a composition-of-matter patent. A biosimilar developer would need to reproduce or sufficiently match the product’s critical quality attributes, delivery presentation, stability profile, and immunogenicity behavior.
Are method-of-use patents important?
Method-of-use claims can protect administration schedules, patient subsets, or treatment of metabolic complications associated with generalized lipodystrophy. Their value depends on claim scope and enforceability. A biosimilar applicant may challenge such claims through a patent certification or litigation strategy while pursuing a label that omits protected indications or dosing language.
Which companies are challenging MYALEPT?
No approved U.S. biosimilar to MYALEPT has been identified in the FDA Purple Book through the publicly reported period covered by the source materials. No established generic competitor has entered the U.S. market.
The competitive field consists primarily of:
- Potential biosimilar developers.
- Academic or specialty companies developing metabolic therapies.
- Off-label metabolic treatments that do not replace leptin.
- Supportive therapies for diabetes, hypertriglyceridemia, and hepatic disease.
These alternatives do not provide a direct substitute for metreleptin in patients with generalized lipodystrophy. Insulin, triglyceride-lowering drugs, GLP-1 medicines, and other metabolic therapies may address complications but do not correct the underlying leptin deficiency.
No publicly disclosed MYALEPT Paragraph IV challenge has become a recognized market event comparable with major small-molecule generic litigation. A Paragraph IV filing is also less straightforward for a BLA product than an ANDA product. A biosimilar applicant would instead operate within the biologics patent-dispute process, including the statutory information-exchange and litigation framework under the Biologics Price Competition and Innovation Act.[5]
What generic entry risks exist for MYALEPT?
The most credible entry risk is a biosimilar, not a conventional generic. The timing risk is moderate rather than immediate because the addressable market is small and development costs are high.
Low near-term risk
Near-term entry risk remains limited because:
- The product has a narrow indication.
- Patient recruitment would be difficult.
- Biosimilar development requires specialized biologic analytics.
- Reimbursement and specialty distribution capabilities are necessary.
- MYALEPT has an established safety and prescribing history.
- The commercial opportunity may not justify development costs for many manufacturers.
Medium- to long-term risk
Risk increases if:
- A biosimilar developer targets several rare metabolic biologics as a portfolio.
- Chiesi’s net pricing rises materially.
- Payers impose stronger step-edit or substitution requirements.
- New leptin-replacement formulations reduce injection burden.
- Patent or regulatory barriers weaken.
- A competitor obtains a broader lipodystrophy indication.
A biosimilar could initially obtain limited uptake because physicians may be reluctant to switch stable patients with a rare and serious disorder. New starts would be more vulnerable to payer-preferred products.
How strong is the MYALEPT commercial franchise?
MYALEPT has a strong niche franchise but a narrow growth ceiling.
| Strength |
Assessment |
| Clinical differentiation |
High for generalized lipodystrophy |
| Market exclusivity |
Reduced after February 2021 orphan-expiry date |
| Patient concentration |
High |
| Pricing power |
Meaningful but constrained by specialty payers |
| Manufacturing barrier |
High relative to conventional generics |
| Biosimilar threat |
Low near term, credible over the longer term |
| Geographic diversification |
Limited |
| Revenue concentration risk |
High |
| Lifecycle expansion |
Limited unless new indications or formulations emerge |
The product’s strongest defense is the combination of clinical necessity, scarce patient population, physician familiarity, and manufacturing complexity. Its main weakness is revenue concentration. A single pricing decision, payer restriction, safety signal, or competitor launch could have an outsized effect on sales.
What licensing deals and ownership changes affect MYALEPT?
Aegerion Pharmaceuticals developed and commercialized MYALEPT after FDA approval. Aegerion later underwent financial restructuring and became part of Amryt Pharma’s portfolio. Amryt expanded the product’s commercial position and reported MYALEPT as a central revenue contributor.
Chiesi acquired Amryt in 2023 for approximately $1.25 billion. The transaction transferred MYALEPT to a privately held pharmaceutical company with an established rare-disease commercial organization.[3]
The ownership sequence is commercially relevant because:
- Aegerion’s financial distress created continuity risk before the Amryt period.
- Amryt used MYALEPT as an anchor product in its rare-disease strategy.
- Chiesi’s larger infrastructure may support supply, reimbursement, and international commercialization.
- Chiesi’s private ownership reduces product-level public disclosure.
What revenue exposure does Chiesi have to MYALEPT?
MYALEPT was a major share of Amryt’s revenue before acquisition. Chiesi’s overall portfolio is much larger and more diversified, so MYALEPT represents a smaller proportion of the acquiring company’s total financial base.
For Chiesi, MYALEPT is best viewed as a durable specialty product rather than a high-growth platform. Its value lies in recurring revenue, limited direct competition, and strategic fit with rare metabolic diseases. The principal financial risks are erosion from biosimilar entry, payer pressure, manufacturing interruption, and declining diagnosis-driven growth.
What generic launch scenarios are most likely?
| Scenario |
Timing |
Market impact |
| No biosimilar entry |
2024-2027 |
Stable specialty revenue with pricing pressure |
| Single biosimilar entrant |
2027-2030 |
New-patient share loss and payer discounts |
| Multiple biosimilars |
After 2030 |
Material price erosion and switching pressure |
| New leptin-replacement formulation |
Uncertain |
Potential differentiation or franchise defense |
| Expanded indication |
Uncertain |
Larger market but higher regulatory and safety burden |
A first biosimilar would probably focus on new patients and payer contracts before pursuing broad conversion of established MYALEPT users. Price erosion would likely be slower than in a conventional small-molecule market because of physician oversight, immunogenicity concerns, and the small number of prescribers.
Key Takeaways
- MYALEPT is metreleptin, a biologic approved for congenital and acquired generalized lipodystrophy.
- FDA approval occurred on February 24, 2014.
- Seven-year orphan exclusivity expired in February 2021.
- Amryt reported MYALEPT revenue of approximately $180 million to $185 million in 2022.
- Chiesi acquired Amryt in 2023 for approximately $1.25 billion.
- The United States remains the principal commercial market.
- No conventional generic pathway applies; a competitor would generally pursue a biosimilar strategy.
- No approved U.S. MYALEPT biosimilar or major publicly reported Paragraph IV market challenge had emerged through the cited reporting period.
- The commercial franchise is strong within a narrow indication but exposed to revenue concentration and future biosimilar competition.
- Patent, formulation, manufacturing, and regulatory barriers remain relevant after orphan exclusivity expiry.
FAQs About MYALEPT Market and Exclusivity
Is MYALEPT still under patent protection?
Potentially relevant patent and patent-family rights may remain depending on claim scope, expiration, and enforceability. Orphan exclusivity expired in 2021, but that date does not establish the end of all patent or manufacturing protection.
Can a generic company make MYALEPT?
A conventional ANDA generic is not the expected route because MYALEPT is a biologic. A competitor would generally need to develop a biosimilar under the 351(k) pathway.
Does MYALEPT have an FDA-approved biosimilar?
No approved U.S. MYALEPT biosimilar was identified in the cited FDA materials and public reporting.
Why is MYALEPT expensive?
MYALEPT is a specialized recombinant protein used by a small patient population. Its price reflects biologic manufacturing, specialty distribution, chronic treatment, safety monitoring, and the absence of a direct approved substitute.
What would most reduce MYALEPT sales?
The largest risks are a clinically accepted biosimilar, payer-preferred substitution, a safety-related label change, manufacturing disruption, or development of a competing leptin-replacement therapy.
References
-
U.S. Food and Drug Administration. (2014). MYALEPT (metreleptin) prescribing information. FDA.
-
Amryt Pharma plc. (2023). Annual report and audited financial statements for the year ended December 31, 2022. Amryt Pharma.
-
Chiesi Farmaceutici S.p.A. (2023). Chiesi completes acquisition of Amryt Pharma. Chiesi Farmaceutici.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.
